First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [41] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
    Lundkvist, J.
    Paulsson, T.
    Borgstrom, F.
    Kasteng, F.
    Sobocki, P.
    Lidgren, M.
    Henriksson, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
  • [42] Fulvestrant A Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2011, 71 (03) : 363 - 380
  • [43] A randomized phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer: First results
    Quenel-Tueux, N.
    Dalenc, F.
    Bachelot, T.
    Pulido, M.
    Bonnefoi, H.
    Mauriac, L.
    Madranges, N.
    Iggo, R.
    Lortal, B.
    de Lara, C. Tunon
    Campo, P.
    Debled, M.
    CANCER RESEARCH, 2013, 73
  • [44] COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Rudakova, A., V
    VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
  • [45] A role for fulvestrant monotherapy in the first-line treatment of ER plus metastatic breast cancer?
    Mahtani, Reshma L.
    BREAST JOURNAL, 2020, 26 (02): : 109 - 111
  • [46] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Borrego, M. Ruiz
    De la Haba, J.
    Morales, S.
    Ramos, M.
    Velasco, A.
    Mendez, M.
    Carabantes, F.
    Barnadas, A.
    Garcia, M.
    Moreno, J. A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
  • [47] Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan
    Verin Lertjanyakun
    Nathorn Chaiyakunapruk
    Susumu Kunisawa
    Yuichi Imanaka
    PharmacoEconomics, 2018, 36 : 1113 - 1124
  • [48] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Ruiz, Manuel
    De la Haba, Juan
    Morales, Serafin
    Ramos, Manuel
    Velasco, Amlia
    Mendez, Miguel
    Carabantes, Francisco
    Barnadas, Agusti
    Garcia, Maria
    Moreno, Jose A.
    ANNALS OF ONCOLOGY, 2004, 15 : 35 - 35
  • [49] Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
    Nathalie Quenel-Tueux
    Marc Debled
    Justine Rudewicz
    Gaetan MacGrogan
    Marina Pulido
    Louis Mauriac
    Florence Dalenc
    Thomas Bachelot
    Barbara Lortal
    Christelle Breton-Callu
    Nicolas Madranges
    Christine Tunon de Lara
    Marion Fournier
    Hervé Bonnefoi
    Hayssam Soueidan
    Macha Nikolski
    Audrey Gros
    Catherine Daly
    Henry Wood
    Pamela Rabbitts
    Richard Iggo
    British Journal of Cancer, 2015, 113 : 585 - 594
  • [50] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
12345